Discovering new antimicrobial agents.

Although there has been a relentless increase in resistance to antimicrobial agents amongst important bacterial pathogens throughout the world, it is well known that the number of new antimicrobial agents being brought to the market has undergone a steady decline in the past several decades. There are a number of reasons for this, which are detailed in this article, but there is also a great deal of continuing research to find new effective antimicrobials, much of it now being carried out in academic centres and especially in small biotechnology companies, rather than by large pharma. Whilst classic screening methods and chemical modification of known antimicrobial agents continue to produce potential leads for new antimicrobial agents, a number of other approaches are being investigated. These include the search for potentiators of the activity of known antimicrobial agents and the development of hybrid agents, novel membrane-active drugs, and inhibitors of bacterial virulence and pathogenesis. A number of new bacterial targets are also being exploited, as are bacteriophages and their lytic enzymes. Given the amount of investigation presently underway, it is clear that although the antibiotic pipeline is not as promising as it was half a century ago, it is far from dry.

[1]  Zhong Chen,et al.  Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala. , 1999, Science.

[2]  R. Breaker,et al.  Antibacterial lysine analogs that target lysine riboswitches. , 2007, Nature chemical biology.

[3]  T. Louie,et al.  OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C. difficile Infection , 2008, Antimicrobial Agents and Chemotherapy.

[4]  V. Saba,et al.  Use of the quorum-sensing inhibitor RNAIII-inhibiting peptide to prevent biofilm formation in vivo by drug-resistant Staphylococcus epidermidis. , 2003, The Journal of infectious diseases.

[5]  W. Shi,et al.  Systematic Approach to Optimizing Specifically Targeted Antimicrobial Peptides against Streptococcus mutans , 2010, Antimicrobial Agents and Chemotherapy.

[6]  K. LaPlante,et al.  Telavancin: a novel lipoglycopeptide antimicrobial agent. , 2007, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[7]  J. Koehn,et al.  N-Alkyl Urea Hydroxamic Acids as a New Class of Peptide Deformylase Inhibitors with Antibacterial Activity , 2002, Antimicrobial Agents and Chemotherapy.

[8]  M. Mammen,et al.  Telavancin Disrupts the Functional Integrity of the Bacterial Membrane through Targeted Interaction with the Cell Wall Precursor Lipid II , 2009, Antimicrobial Agents and Chemotherapy.

[9]  R. J. Doerksen,et al.  Nontoxic membrane-active antimicrobial arylamide oligomers. , 2004, Angewandte Chemie.

[10]  Alexis Criscuolo,et al.  Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. , 2010, The Journal of infectious diseases.

[11]  R. Moellering Rationale for use of antimicrobial combinations. , 1983, The American journal of medicine.

[12]  M. Zervos,et al.  Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  T. Pruett Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America , 2010 .

[14]  A. So,et al.  Tackling antibiotic resistance , 2010, BMJ : British Medical Journal.

[15]  D. Bertrand,et al.  Molecular Characterization of Off-Target Activities of Telithromycin: a Potential Role for Nicotinic Acetylcholine Receptors , 2010, Antimicrobial Agents and Chemotherapy.

[16]  Timothy R. Walsh,et al.  Tackling antibiotic resistance , 2011, Nature Reviews Microbiology.

[17]  K. Krause,et al.  Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia. , 2010, The Journal of antimicrobial chemotherapy.

[18]  Martha S. Head,et al.  Discovery of a Novel and Potent Class of FabI-Directed Antibacterial Agents , 2002, Antimicrobial Agents and Chemotherapy.

[19]  G. Bammert,et al.  Discovery and Characterization of QPT-1, the Progenitor of a New Class of Bacterial Topoisomerase Inhibitors , 2008, Antimicrobial Agents and Chemotherapy.

[20]  O. Levy A Neutrophil-Derived Anti-Infective Molecule: Bactericidal/Permeability-Increasing Protein , 2000, Antimicrobial Agents and Chemotherapy.

[21]  G. Talbot,et al.  In Vitro Profiling of Ceftaroline against a Collection of Recent Bacterial Clinical Isolates from across the United States , 2008, Antimicrobial Agents and Chemotherapy.

[22]  J. Lipuma,et al.  In Vitro Activities of a Novel Nanoemulsion against Burkholderia and Other Multidrug-Resistant Cystic Fibrosis-Associated Bacterial Species , 2008, Antimicrobial Agents and Chemotherapy.

[23]  P. Silley,et al.  Mode of action of GR69153, a novel catechol-substituted cephalosporin, and its interaction with the tonB-dependent iron transport system , 1990, Antimicrobial Agents and Chemotherapy.

[24]  D. Skow,et al.  Antibacterial Activity and Mechanism of Action of a Novel Anilinouracil-Fluoroquinolone Hybrid Compound , 2007, Antimicrobial Agents and Chemotherapy.

[25]  Gracia Morales,et al.  Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  D. Nicolau,et al.  In Vitro Potency of CXA-101, a Novel Cephalosporin, against Pseudomonas aeruginosa Displaying Various Resistance Phenotypes, Including Multidrug Resistance , 2009, Antimicrobial Agents and Chemotherapy.

[27]  C. Mant,et al.  Role of Peptide Hydrophobicity in the Mechanism of Action of α-Helical Antimicrobial Peptides , 2006, Antimicrobial Agents and Chemotherapy.

[28]  Chad W. Euler,et al.  Synergism between a Novel Chimeric Lysin and Oxacillin Protects against Infection by Methicillin-Resistant Staphylococcus aureus , 2010, Antimicrobial Agents and Chemotherapy.

[29]  D. Shlaes,et al.  The pleuromutilin antibiotics: a new class for human use. , 2010, Current opinion in investigational drugs.

[30]  R. Hancock Peptide antibiotics , 1997, The Lancet.

[31]  T. Nicas,et al.  Mechanism of action of oritavancin and related glycopeptide antibiotics. , 2003, FEMS microbiology reviews.

[32]  A. Fothergill,et al.  NB-002, a Novel Nanoemulsion with Broad Antifungal Activity against Dermatophytes, Other Filamentous Fungi, and Candida albicans , 2009, Antimicrobial Agents and Chemotherapy.

[33]  S. Bhavnani,et al.  Oritavancin Population Pharmacokinetics in Healthy Subjects and Patients with Complicated Skin and Skin Structure Infections or Bacteremia , 2009, Antimicrobial Agents and Chemotherapy.

[34]  R. Flamm,et al.  In Vitro and Bactericidal Activities of ABT-492, a Novel Fluoroquinolone, against Gram-Positive and Gram-Negative Organisms , 2004, Antimicrobial Agents and Chemotherapy.

[35]  M. Page,et al.  In Vitro Properties of BAL30072, a Novel Siderophore Sulfactam with Activity against Multiresistant Gram-Negative Bacilli , 2010, Antimicrobial Agents and Chemotherapy.

[36]  I. Chopra,et al.  XF-70 and XF-73, novel antibacterial agents active against slow-growing and non-dividing cultures of Staphylococcus aureus including biofilms. , 2010, The Journal of antimicrobial chemotherapy.

[37]  P. Charifson,et al.  Dual Targeting of GyrB and ParE by a Novel Aminobenzimidazole Class of Antibacterial Compounds , 2006, Antimicrobial Agents and Chemotherapy.

[38]  Angela Lee,et al.  Identification and Characterization of Inhibitors of Multidrug Resistance Efflux Pumps in Pseudomonas aeruginosa: Novel Agents for Combination Therapy , 2001, Antimicrobial Agents and Chemotherapy.

[39]  J. Fox The business of developing antibacterials , 2006, Nature Biotechnology.

[40]  Robert E W Hancock,et al.  Effects of Hydrophobicity on the Antifungal Activity of α‐Helical Antimicrobial Peptides , 2008, Chemical biology & drug design.

[41]  V. Fischetti,et al.  Reinventing phage therapy: are the parts greater than the sum? , 2006, Nature Biotechnology.

[42]  R. Breaker RNA Second Messengers and Riboswitches: Relics from the RNA World?: Some riboswitches and their ligands may be relics of signaling networks used when organisms relied on RNA instead of DNA and proteins , 2010 .

[43]  R. Moellering Can the third-generation cephalosporins eliminate the need for antimicrobial combinations? , 1985, The American journal of medicine.

[44]  N. Georgopapadakou,et al.  Mechanisms of action of cephalosporin 3'-quinolone esters, carbamates, and tertiary amines in Escherichia coli , 1993, Antimicrobial Agents and Chemotherapy.

[45]  N. Curtis,et al.  Iron-regulated outer membrane proteins of Escherichia coli K-12 and mechanism of action of catechol-substituted cephalosporins , 1988, Antimicrobial Agents and Chemotherapy.

[46]  U. Theuretzbacher,et al.  Future antibiotics scenarios: is the tide starting to turn? , 2009, International journal of antimicrobial agents.

[47]  G. Igrejas,et al.  In vitro activity of ceftobiprole against Gram-positive and Gram-negative bacteria isolated from humans and animals. , 2010, Journal of Antimicrobial Chemotherapy.

[48]  J. Garnacho-Montero,et al.  Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  H. Sahl,et al.  New insights into the mechanism of action of lantibiotics--diverse biological effects by binding to the same molecular target. , 2000, The Journal of antimicrobial chemotherapy.

[50]  D. Pompliano,et al.  Drugs for bad bugs: confronting the challenges of antibacterial discovery , 2007, Nature Reviews Drug Discovery.

[51]  Phil Barton,et al.  Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial , 2000, The Lancet.

[52]  G. Vovis,et al.  Genomics and Antimicrobial Drug Discovery , 1999, Antimicrobial Agents and Chemotherapy.

[53]  D. Stevens,et al.  Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. , 2007, The Journal of infectious diseases.

[54]  T. Stachyra,et al.  In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor , 2004 .

[55]  D. Pritchard,et al.  Quorum sensing: a novel target for anti-infective therapy. , 1998, The Journal of antimicrobial chemotherapy.

[56]  J. Mond,et al.  Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model. , 2007, The Journal of antimicrobial chemotherapy.

[57]  G. Zurenko,et al.  In Vitro Activity of TR-700, the Active Ingredient of the Antibacterial Prodrug TR-701, a Novel Oxazolidinone Antibacterial Agent , 2009, Antimicrobial Agents and Chemotherapy.

[58]  Brad Spellberg,et al.  The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[59]  D. Sahm,et al.  Comparative In Vitro Activity Profile of Oritavancin against Recent Gram-Positive Clinical Isolates , 2009, Antimicrobial Agents and Chemotherapy.

[60]  R. Bonomo,et al.  Three Decades of β-Lactamase Inhibitors , 2010, Clinical Microbiology Reviews.